Retrospective Evaluation of Hairy Cell Leukemia Patients: Single Center Experience
Eastern Journal of Medicine, cilt.29, sa.4, ss.600-604, 2024 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 29 Sayı: 4
- Basım Tarihi: 2024
- Doi Numarası: 10.5505/ejm.2024.08683
- Dergi Adı: Eastern Journal of Medicine
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.600-604
- Anahtar Kelimeler: Cladribine, Hairy Cell Leukemia, OS, Pentostatin, PFS, Rituximab
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Hairy cell leukemia (HCL) is a rare B-cell leukemia. This study aimed to investigate the clinical and demographic features and treatment responses of HCL patients diagnosed and treated at our center. Thirteen patients were diagnosed between March 2019 and February 2024. Morphology, immunohistochemistry, and flow cytometry were used for diagnosis. All patients received cladribine as first-line treatment. Patients with partial response or less and those who relapsed received salvage therapy. The median age of the patients was 53. Seven patients (53.8%) had pancytopenia. BRAF V600E mutation was positive in 9 patients (69%). Splenomegaly was present in 10 patients (76.9%) at diagnosi s. Cladribine treatment achieved complete response in 11 patients (84%), partial response in 1 patient (7%). One patient did not respond to treatment. Two patients relapsed and achieved complete remission with pentostatin or rituximab treatment. The 5-year overall survival (OS) rate was 92.3% and progression-free survival (PFS) rate was 84.6%. The demographic and laboratory features and treatment outcomes of HCL patients followed at our center are consistent with the literature. Cladribine is highly effecti ve as a first-line treatment in HCL and provides high response rates. Pentostatin and rituximab monotherapy were found to be effective in relapsed patients.